Hormonal
Once-weekly subcutaneous semaglutide (specifically the 2.4 mg dose) produces substantial, sustained weight loss (mean reduction ~14.9%) and significant improvements in cardiometabolic risk factors (HbA1c, lipids, blood pressure) in adults with overweight or obesity, with an acceptable safety profile characterized by mild-to-moderate gastrointestinal side effects.
If you have obesity or overweight with comorbidities, once-weekly semaglutide (2.4 mg) is a highly effective medical treatment that can help you lose nearly 15% of your body weight and improve heart health markers like blood pressure and cholesterol. While you may experience temporary stomach issues like nausea when starting, these usually get better as your body adjusts. It is not a quick fix but a long-term management tool for a chronic condition, comparable to how medication manages high blood pressure.
Overall, once-weekly semaglutide produces substantial and sustained weight loss with meaningful metabolic benefits and an acceptable safety profile, supporting its role as an effective pharmacological option for the management of obesity.
Why this rating
Systematic review of 36 randomized controlled trials involving 23,184 participants, using random-effects models and Cochrane RoB 2 assessment.
Source
Effectiveness and safety of once-weekly semaglutide for weight loss in adults with overweight or obesity: a systematic review of randomized controlled trials
Snehashis Singha et al. · International Journal of Basic & Clinical Pharmacology · 2026
DOI 10.18203/2319-2003.ijbcp20260439
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →